| Stereochemistry | ABSOLUTE |
| Molecular Formula | C47H51NO15 |
| Molecular Weight | 869.9055 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 11 / 11 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]4(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C5=CC=CC=C5)C6=CC=CC=C6)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]7OC[C@@]27OC(=O)OC)C4(C)C
InChI
InChIKey=GMJWGJSDPOAZTP-MIDYMNAOSA-N
InChI=1S/C47H51NO15/c1-25-30(61-42(55)35(51)34(27-16-10-7-11-17-27)48-40(53)28-18-12-8-13-19-28)23-47(57)39(62-41(54)29-20-14-9-15-21-29)37-45(5,38(52)36(60-26(2)49)33(25)44(47,3)4)31(50)22-32-46(37,24-59-32)63-43(56)58-6/h7-21,30-32,34-37,39,50-51,57H,22-24H2,1-6H3,(H,48,53)/t30-,31-,32+,34-,35+,36+,37-,39-,45+,46-,47+/m0/s1
Bristol-Myers Squibb developed BMS-188797 for the potential treatment of solid tumors. BMS-188797 causes G2/M cell cycle arrest and exhibits potent antiproliferative activity against human tumor cell. BMS-188797 in combination with cisplatin successfully has passed phase I clinical and has been recommended for further phase II trials. However, further development has been halted.
Approval Year
PubMed
Patents
SUBSTANCE RECORD
